All In Biotech

Drug Trial Radar · NCT05222529

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Bromide) in Children From 6 to Less Than 12 Years of Age With Asthma.

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Aug 29, 2022

Primary completion

Jul 30, 2027

Study completion Aug 30, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo. Outcome of this study will be used to determine the dose of inhaled glycopyrronium for the development of fixed dose combination indacaterol/mometasone/glycopyrronium (QVM149) for children aged 6 to less than 12 years old with moderate to severe asthma.

Conditions

  • Asthma

Interventions

  • Glycopyrronium bromide 25ugDrug

    25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler

  • PlaceboDrug

    Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler

  • Glycopyrronium bromide 12.5ugDrug

    12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in trough FEV1Time frame: At the start and end of each 2 week treatment period (Days 1, 14, 29, 42, 57 and 70)

Locations

23 sites in 8 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Rousse, Bulgaria · Recruiting

  • Novartis Investigative Site

    Sevlievo, Bulgaria · Recruiting

  • Novartis Investigative Site

    Sofia, Bulgaria · Recruiting

  • Novartis Investigative Site

    Ibague, Tolima Department, Colombia · Recruiting

  • Novartis Investigative Site

    Guatemala City, Guatemala · Recruiting

  • Novartis Investigative Site

    Guatemala City, GTM, Guatemala · Withdrawn

  • Novartis Investigative Site

    Budapest, Hungary · Recruiting

  • Novartis Investigative Site

    Budapest, Hungary · Recruiting

  • Novartis Investigative Site

    Eger, Hungary · Recruiting

  • Novartis Investigative Site

    Kaposvár, Hungary · Withdrawn

  • Novartis Investigative Site

    Nagykanizsa, Hungary · Withdrawn

  • Novartis Investigative Site

    Szigetvár, Hungary · Recruiting

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, Hungary · Recruiting

  • Novartis Investigative Site

    Lodz, Łódź Voivodeship, Poland · Recruiting

  • Novartis Investigative Site

    Tarnów, Poland, Poland · Recruiting

  • Novartis Investigative Site

    Cape Town, South Africa · Recruiting

  • Novartis Investigative Site

    George, Western Cape, South Africa · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Esplugues, Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Sabadell, Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Mérida, Extremadura, Spain · Withdrawn

  • Novartis Investigative Site

    London, United Kingdom · Recruiting

  • Novartis Investigative Site

    Stoke-on-Trent, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.